ENBIOSIS Biotechnology
Enbiosis is a B2B biotechnology company that leverages whole-genome sequencing, artificial intelligence, and clinical data to deliver personalized nutrition and supplement plans that modulate the gut microbiome for improved health outcomes. Their SaaS platform provides actionable, AI-powered clinical insights and personalized food and supplement recommendations based on gut microbiome analysis, targeting conditions such as IBS, chronic constipation, and other gut-related health issues. Supported by peer-reviewed clinical studies and validated by the UK Government, Enbiosis serves healthcare providers, pharmaceutical companies, telehealth services, and wellness centers globally, with over 4,000 patients treated and proven success rates in symptom improvement. The company is recognized internationally with multiple awards and continues expanding its global footprint in precision health and longevity markets.
ENBIOSIS Biotechnology
Enbiosis is a B2B biotechnology company that leverages whole-genome sequencing, artificial intelligence, and clinical data to deliver personalized nutrition and supplement plans that modulate the gut microbiome for improved health outcomes. Their SaaS platform provides actionable, AI-powered clinical insights and personalized food and supplement recommendations based on gut microbiome analysis, targeting conditions such as IBS, chronic constipation, and other gut-related health issues. Supported by peer-reviewed clinical studies and validated by the UK Government, Enbiosis serves healthcare providers, pharmaceutical companies, telehealth services, and wellness centers globally, with over 4,000 patients treated and proven success rates in symptom improvement. The company is recognized internationally with multiple awards and continues expanding its global footprint in precision health and longevity markets.
TL;DR
Founded: 2019
Headquarters: London, UK
Core offering: AI-powered gut microbiome analysis with personalized nutrition and supplement recommendations
Customers: Healthcare providers, pharma, telehealth services, wellness centers
Reported patients treated: Over 4,000
Seed rounds; latest recorded Apr 10, 2023
